Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Circulation. 2020 Jun 30;142(9):858–867. doi: 10.1161/CIRCULATIONAHA.120.046321

Table 1:

Patient Population (91 subjects that experienced an event and were followed for at least 90 days) in the ICD cohort during the study period from September 1, 2006 until June 30, 2010

Subjects with any type of VA Subjects with sustained VA
N
(Total)
N
(with characteristics)
N
(Total)
N
(with characteristics)
Age (years) 91 65.0 (33–89) 25 62.0 (37–86)
Gender (male) 91 70 (77%) 25 21 (84%)
Race 91 25
 White 83 (91%) 23 (92%)
 Black 7 (8%) 2 (8%)
 Other 1 (1%)
BMI (kg/m2) 91 27.7 (15.6–56.7) 25 29.6 (21.7–55.6)
Structural heart disease 91 25
 Ischemic 57 (63%) 18 (72%)
 Nonischemic 26 (29%) 6 (24%)
 Other 9 (10%) 2 (8%)
Left ventricular ejection fraction (%) 90 25.0 (10–70) 25 25 (10–55)
History of congestive heart failure 91 55 (60%) 25 15 (60%)
 CHF class I 13 (14%) 4 (16%)
  II 19 (21%) 5 (20%)
  III 23 (25%) 6 (24%)
  IV
Co-morbidities
 Pulmonary Disease 91 17 (19%) 25 4 (16%)
 Diabetes 89 28 (46%) 24 7 (29%)
 Hypertension 88 52 (59%) 25 18 (72%)
Medications
 Beta blocker 88 84 (95%) 25 24 (96%)
 Antiarrhythmic agents: (Amiodarone, sotalol, or others not including beta blockers) 88 10 (11%) 25 5 (20%)
 Platelet Aggregation Inhibitors 88 66 (75%) 25 19 (76%)
Smoking
 Current 86 10 (12%) 25 3 (12%)
 Former 73 46 (63%) 21 11 (52%)
 Never 82 56 (68%) 24 14 (58%)
 Lived with Smoker 91 57 (63%) 25 17 (68%)

Values are median (range) or n (%). Values may not always add up to 91 or 25 because of missing data. VA= ventricular arrhythmias; BMI= body mass index; CHF= congestive heart failure